ESPOO, Finland, Dec. 17, 2013 (GLOBE NEWSWIRE) -- Eurofins Medigenomix, a part of the Eurofins Genomics Business line of Eurofins Scientific and Orion Diagnostica Oy, an in vitro diagnostics company specialising in the development, production and sales of diagnostic test systems, announced that they have signed a co-exclusive technology license agreement. Orion Diagnostica Oy owns the global rights for the SIBA® isothermal nucleic acid detection technology in all fields. "Our general focus is to translate innovative and new technologies into new applications of DNA based analysis. This will allow our Eurofins Genomics business line to generate the high service level we want to provide to our customers", said Bruno Poddevin, Senior Vice President, Eurofins Genomics. "The SIBA technology and the associated expertise of Orion Diagnostica are an excellent fit for Eurofins. The cooperation will allow us to broaden Eurofins' portfolio with innovative analytical solutions particularly in the area of DNA based authenticity testing for food and related products", added Peter Persigehl, Managing Director of Eurofins Medigenomix. "Orion Diagnostica's new SIBA technology allows a fast, robust, and reliable detection of nucleic acids from a variety of sources and for different identification needs enabling wide range of uses in different fields. We are delighted to enter into this agreement with Eurofins Medigenomix, a leader in the field of Genetic Analyses, and look forward to collaborating on projects such as authenticity testing for clients worldwide," said Jaakko Rissanen, President, Orion Diagnostica Oy. About Eurofins Medigenomix Eurofins Medigenomix (Ebersberg, Germany) is a member of the Eurofins Genomics division of the Eurofins Scientific group, a life science company with laboratories in 37 countries and over 15,000 employees. The Eurofins Genomics division is an international provider of genomic services and applied solutions for agroscience, food, forensics, pharma discovery, diagnostics, biotechnological and research markets around the core business lines next generation sequencing, genotyping, gene expression, custom DNA sequencing, DNA, RNA and gene synthesis. Please visit www.eurofinsgenomics.com for more information. About Orion Diagnostica Oy Orion Diagnostica Oy (Espoo, Finland) is part of Orion Group, the leading health care company in Finland. Orion Diagnostica develops, manufactures, and markets diagnostic tests. It specialises in easy-to-use, cost-effective clinical in vitro diagnostic tests and hygiene monitoring solutions designed to improve health care effectiveness and individual well-being. The special focus is on products for primary health care that enable consultation, testing, and treatment decisions to be completed during a single patient visit. Please visit www.oriondiagnostica.com for further information. About SIBA® technology - a novel technology for isothermal amplification and detection of nucleic acids providing fast and accurate results for various laboratory settings. SIBA® (Strand Invasion Based Amplification) is a novel isothermal nucleic acid amplification technology, relying on the recombinase-dependent invasion of an oligonucleotide into the double-stranded target nucleic acid which leads to dissociation of the double-stranded nucleic acid. Dissociation of the target nucleic acid enables specific primers to amplify the target exponentially by the action of a polymerase. The primers are unable to amplify target nucleic acid independently of the invasion oligonucleotide, thus making the amplification highly specific even in multi-targeted reactions. Proven tolerance to sample-derived inhibitors allows the SIBA technology to robustly distinguish closely related species with high sensitivity. The SIBA technology perfoms at a low and constant temperature obviating the need of complex thermal cycling instrumentation. The strengths of the SIBA technology favour the use of the technology in a variety of sample types and test settings in a small-footprint device.
Further information:Orion Diagnostica Oy Jaakko Rissanen, President Email: email@example.com Tel. + 358 10 426 4858 Aino Takala, Vice President, Business Development Email: firstname.lastname@example.org Tel. +358 10 426 4503 Eurofins Medigenomix GmbH Peter Persigehl, Managing Director Email: email@example.com Tel. +49 8092 8289-991 Publisher: Orion Corporation Communications Orionintie 1A, FI-02200 Espoo, Finland www.orion.fi Press release http://hugin.info/3079/R/1750079/589601.pdf HUG#1750079